LECTURE

From biology to therapy: progress in acute promyelocytic leukemia
M.T. Voso
SESSION I

ACUTE MYELOID LEUKEMIA

Emerging targeted therapies and combinations
A. Venditti
Novel strategies to treat older patients
F. Buccisano
Is it maintenance therapy necessary?
A. Isidori
SESSION II

CHRONIC LYMPHOCYTIC LEUKEMIA

Emerging prognostic/predictive factors
I. Del Giudice
Autoimmune complications
M. Coscia
Lessons from clinical trials
P. Ghia
Salvage therapy
F.R. Mauro
SESSION III

MYELOPROLIFERATIVE NEOPLASMS

Post-MPN acute leukemia: a persistently unmet need
P. Guglielmelli
Re-assessing the treatment paradigm of PV
V. De Stefano
Thrombosis and bleeding: rationale and therapeutic perspectives
S. Siragusa
Beyond JAK inhibitors in MF
F. Passamonti
Hypereosinophilias with and without genetic rearrangement
F. Mannelli
SESSION IV

CHRONIC MYELOID LEUKEMIA

Imatinib versus a 2nd generation TKI for the first line of therapy: how we can tip the balance between efficacy and quality of life
M. Tiribelli
The new guidelines for the management of CML
G. Rosti
Future perspectives of novel therapies
M. Breccia
SESSION V

ACUTE LYMPHOBLASTIC LEUKEMIA

MRD driven strategy in Adult ALL
R. Bassan
New treatment strategies for Ph-like ALL
S. Chiaretti
SESSION VI

MYELODYSPLASTIC SYNDROMES

Recent advances in somatic mutations and altered signaling in MDS cell
M.Y. Follo
Towards a new prognostication of MDS
M. Bersanelli
SESSION VII

EXPANDING HORIZONS FOR IMMUNOTHERAPY IN ONCO-HEMATOLOGY

State of the art
A.J.M. Ferreri
CAR-T in Indolent NHL
A. Pulsoni
New Drugs in NHLs
U. Vitolo
Privacy Policy | Cookie Policy